MaximForte
MaximForte advises founders and family owners of healthcare businesses on valuation, readiness, exit and succession planning, and sell-side M&A. Its stated process includes positioning, confidential buyer outreach, negotiation, and closing.
MaximForte is a healthcare-focused M&A advisory firm serving founders and family owners.
Its public materials describe valuation and readiness assessments, exit and succession planning, sell-side representation, and wealth-transition services described as launching upon effective New York RIA registration.[1][2]
What does MaximForte do?
MaximForte presents itself as a healthcare investment-banking and M&A advisory firm serving founders and family owners of healthcare businesses. Its stated services span estimated valuation and readiness assessments, exit and succession planning, sell-side M&A representation, and wealth-transition services described as launching upon effective New York RIA registration.[1]
Publicly stated services include estimated valuation and readiness assessments, exit and succession planning, and sell-side M&A representation. The firm describes its sell-side work as covering positioning, confidential buyer outreach, negotiation, and closing. It also describes wealth-transition services as launching upon effective New York RIA registration.[1]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring MaximForte?
Owners evaluating MaximForte can clarify how the firm’s healthcare focus applies to their specific subsector and how the published readiness framework would address management depth, customer diversification, financial reporting, compliance, and the growth narrative. Because the cited MaximForte homepage does not identify representative transactions or publish engagement economics, an owner may wish to request healthcare mandates or references, fee and expense terms, exclusivity and termination provisions, any tail period, and the buyer-coverage evidence that would support a proposed process.
Owners should also confirm which legal entity will be party to the engagement and provide each service, the status of the New York investment-adviser application, the availability of any wealth-transition services, and how conflicts are handled through the Finalis relationship.[1][2]
Which legal entity will be party to the engagement and provide each service
What are MaximForte's minimum revenue, EBITDA, enterprise-value, or transaction-size criteria
Can MaximForte provide recent healthcare sell-side references or identify completed transactions under confidentiality
What size transactions and clients does MaximForte focus on?
MaximForte states that it serves healthcare providers and services, wellness and consumer health, pharma services and life sciences, and health tech and allied services. Its published examples include assisted living, behavioral health, home health, physician and veterinary practices, medspas, pharmacies, contract research and manufacturing, laboratories, diagnostics, MedTech, healthcare IT and SaaS, revenue-cycle management, staffing, and healthcare consulting.[1]
The cited MaximForte homepage displays aggregate metrics of 0 transactions closed, $0m realized value, and $0m capital raised, but does not identify individual completed transactions.[1]
The firm’s stated transaction focus is sell-side M&A representation. The described process includes positioning, confidential buyer outreach, negotiation, and closing.[1]
What does MaximForte publicly disclose about fees, process and engagement terms?
The cited MaximForte homepage does not state a minimum or target revenue, EBITDA, enterprise-value, or transaction-size criterion for advisory engagements. The same homepage does not identify named representative transactions, transaction values, buyer identities, closing dates, or consideration terms.
The cited MaximForte homepage also does not publish a fee schedule, success-fee percentage, minimum fee, expense policy, exclusivity term, termination schedule, or tail period.[1]
The cited MaximForte homepage states that securities are offered through Finalis Securities LLC, Member FINRA/SIPC, and that M&A advisory and private-placement activities are conducted through that broker-dealer relationship. It also states that MaximForte LLC is not a registered broker-dealer and that Finalis Securities LLC and MaximForte LLC are separate, unaffiliated entities.
The homepage further states that a registered investment-adviser application is under review with the State of New York and that investment-advisory services will not be offered unless and until registration becomes effective.[1]
MaximForte’s published exit-preparation approach emphasizes advance runway, management depth, customer diversification, professional financial reporting, compliance housekeeping, and documenting a growth narrative before a sale process. Its exit-readiness assessment evaluates business readiness, financial and value readiness, and personal readiness for founders and family owners of private businesses.[2][3]
Questions to ask before hiring MaximForte
Which legal entity will be party to the engagement and provide each service?
What are MaximForte's minimum revenue, EBITDA, enterprise-value, or transaction-size criteria?
Can MaximForte provide recent healthcare sell-side references or identify completed transactions under confidentiality?
How are fees, retainers, success fees, expenses, exclusivity, termination rights, and any tail period structured?
What is the current status of the New York investment-adviser application, and which post-exit wealth services are currently available?
How are conflicts handled through the Finalis relationship?
Sources & research notes
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.
